Cost Analysis in Helicobacter pylori Eradication Therapy Based on a Database of Health Insurance Claims in Japan

References

• Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420–429. doi:10.1053/j.gastro.2017.04.022
   PubMed Web of Science ®Google Scholar
• Kodama M, Murakami K, Okimoto T, et al. Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication. J Gastroenterol. 2012;47(4):394–403. doi:10.1007/s00535-011-0504-9
   PubMed Web of Science ®Google Scholar
• Kato M, Ota H, Okuda M, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 revised edition. Helicobacter. 2019;24(4):e12597. doi:10.1111/hel.12597
   PubMed Web of Science ®Google Scholar
• Asaka M, Kato M, Graham DY. Strategy for eliminating gastric cancer in Japan. Helicobacter. 2010;15(6):486–490. doi:10.1111/j.1523-5378.2010.00799.x
   Web of Science ®Google Scholar
• de Martel C, Forman D, Plummer M. Gastric cancer: epidemiology and risk factors. Gastroenterol Clin North Am. 2013;42(2):219–240. doi:10.1016/j.gtc.2013.01.003
   PubMed Web of Science ®Google Scholar
• Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372(9636):392–397. doi:10.1016/S0140-6736(08)61159-9
   PubMed Web of Science ®Google Scholar
• Tsuda M, Asaka M, Kato M, et al. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter. 2017;22(5):e12415. doi:10.1111/hel.12415
   PubMed Web of Science ®Google Scholar
• National Cancer Center. National cancer center, latest cancer statistics - Japan 2018 [Japanese]. Available from: https://ganjoho.jp/reg_stat/statistics/stat/summary.html. Accessed April 2, 2021.
   Google Scholar
• Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143–1153. doi:10.1136/gut.2009.192757
   PubMed Web of Science ®Google Scholar
• Hashinaga M, Okimoto T, Kodama M. 我が国における薬剤耐性Helicobacter pyloriの現状 [Drug resistance in Japan: the present status of Helicobacter pylori; the overall results of the resistant strain survey in 2013 and 2014]. Jpn J Helicobacter Res. 2016;17(2):45–49. Japanese.
   Google Scholar
• Kawai T, Takahashi S, Suzuki H, et al. Changes in the first line Helicobacter pylori eradication rates using the triple therapy – a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group). J Gastroenterol Hepatol. 2014;29(Suppl 4):29–32. doi:10.1111/jgh.12796
   PubMed Web of Science ®Google Scholar
• Hori Y, Matsukawa J, Takeuchi T, Nishida H, Kajino M, Inatomi N. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther. 2011;337(3):797–804. doi:10.1124/jpet.111.179556
   PubMed Web of Science ®Google Scholar
• Li M, Oshima T, Horikawa T, et al. Systematic review with meta-analysis: vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Helicobacter. 2018;23(4):e12495. doi:10.1111/hel.12495
   PubMed Web of Science ®Google Scholar
• Lyu Q-J, Pu Q-H, Zhong X-F, Zhang J. Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials. Biomed Res Int. 2019;2019:9781212. doi:10.1155/2019/9781212
   PubMed Web of Science ®Google Scholar
• Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a Phase III, randomised, double-blind study. Gut. 2016;65(9):1439–1446. doi:10.1136/gutjnl-2015-311304
   PubMed Web of Science ®Google Scholar
• Farhoud NS, Ibrahim OM, Ezzat SE. Efficacy and cost-effectiveness comparison of 10-day, 14-day sequential versus 14-day triple therapies for treating Helicobacter pylori infection in Egyptian patients. J Clin Gastroenterol. 2020;54(9):806–812. doi:10.1097/MCG.0000000000001278
   Web of Science ®Google Scholar
• Papaefthymiou A, Liatsos C, Georgopoulos SD, et al. Helicobacter pylori eradication regimens in an antibiotic high-resistance European area: a cost-effectiveness analysis. Helicobacter. 2020;25(1):e12666. doi:10.1111/hel.12666
   PubMed Web of Science ®Google Scholar
• Yi D-M, Yang -T-T, Chao S-H, et al. Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study. Medicine (Baltimore). 2019;98(6):e14408. doi:10.1097/MD.0000000000014408
   Web of Science ®Google Scholar
• Kajihara Y, Shimoyama T, Mizuki I. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication. Scand J Gastroenterol. 2017;52(2):238–241. doi:10.1080/00365521.2016.1250157
   PubMed Web of Science ®Google Scholar
• Seko T, Tachi T, Hatakeyama H, Noguchi Y, Teramachi H. Cost-effectiveness analysis and effectiveness of pharmacist-managed outpatient clinics in Helicobacter pylori eradication therapy. Int J Clin Pract. 2019;73(6):e13349. doi:10.1111/ijcp.13349
   PubMed Web of Science ®Google Scholar
• Deguchi H, Uda A, Murakami K. Current status of Helicobacter pylori diagnosis and eradication therapy in Japan using a nationwide database. Digestion. 2020;101(4):441–449. doi:10.1159/000500819
   Web of Science ®Google Scholar
• Deguchi H, Yamazaki H, Yamamoto Y, Fukuhara S. Association between parental history of Helicobacter pylori treatment failure and treatment failure in the offspring. J Gastroenterol Hepatol. 2019;34(12):2112–2117. doi:10.1111/jgh.14774
   Web of Science ®Google Scholar
• Mori H, Suzuki H, Omata F, et al. Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: a multicenter study with a large number of patients. Therap Adv Gastroenterol. 2019;12:1756284819858511. doi:10.1177/1756284819858511
   Web of Science ®Google Scholar
• Hirayama Y, Kawai T, Otaki J, Kawakami K, Harada Y. Prevalence of Helicobacter pylori infection with healthy subjects in Japan. J Gastroenterol Hepatol. 2014;29(Suppl 4):16–19. doi:10.1111/jgh.12795
   PubMed Web of Science ®Google Scholar
• Hiroi S, Sugano K, Tanaka S, Kawakami K. Impact of health insurance coverage for Helicobacter pylori gastritis on the trends in eradication therapy in Japan: retrospective observational study and simulation study based on real-world data. BMJ Open. 2017;7(7):e015855. doi:10.1136/bmjopen-2017-015855
   Web of Science ®Google Scholar
• Sugano K, Hiroi S, Yamaoka Y. Prevalence of Helicobacter pylori infection in Asia: remembrance of things past? Gastroenterology. 2018;154(1):257–258. doi:10.1053/j.gastro.2017.08.074
   Web of Science ®Google Scholar
• Ozaki H, Harada S, Takeuchi T, et al. Vonoprazan, a novel potassium-competitive acid blocker, should be used for the Helicobacter pylori eradication therapy as first choice: a large sample study of vonoprazan in real world compared with our randomized control trial using second-generation proton pump inhibitors for Helicobacter pylori eradication therapy. Digestion. 2018;97(3):212–218. doi:10.1159/000485097
   PubMed Web of Science ®Google Scholar
• Meteo. Medical*online [Japanese]. Available from: http://pha.medicalonline.jp. Accessed April 2, 2021.
   Google Scholar
• Higuchi K, Maekawa T, Nakagawa K, et al. Efficacy and safety of Helicobacter pylori eradication therapy with omeprazole, amoxicillin and high- and low-dose clarithromycin in Japanese patients: a randomised, double-blind, multicentre study. Clin Drug Investig. 2006;26(7):403–414. doi:10.2165/00044011-200626070-00002
   Web of Science ®Google Scholar
• Miwa H, Murai T, Sato K, et al. Comparison of the efficacy of 400mg and 800mg of clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection in a Japanese population. J Gastroenterol. 2000;35(7):536–539. doi:10.1007/s005350070077
   Web of Science ®Google Scholar
• Abdullahi M, Annibale B, Capoccia D, et al. The eradication of Helicobacter pylori is affected by body mass index (BMI). Obes Surg. 2008;18(11):1450–1454. doi:10.1007/s11695-008-9477-z
   PubMed Web of Science ®Google Scholar
• Ishioka H, Mizuno M, Take S, et al. A better cure rate with 800 mg than with 400 mg clarithromycin regimens in one-week triple therapy for Helicobacter pylori infection in cigarette-smoking peptic ulcer patients. Digestion. 2007;75(2–3):63–68. doi:10.1159/000102301
   Web of Science ®Google Scholar
• Longo C, Bartlett G, Macgibbon B, et al. The effect of obesity on antibiotic treatment failure: a historical cohort study. Pharmacoepidemiol Drug Saf. 2013;22(9):970–976. doi:10.1002/pds.3461
   PubMed Web of Science ®Google Scholar
• Ashida K, Honda Y, Sanada K, Takemura Y, Sakamoto S. The safety and effectiveness of vonoprazan-based Helicobacter pylori eradication therapy; a prospective post-marketing surveillance. Expert Opin Drug Saf. 2019;18(12):1255–1261. doi:10.1080/14740338.2019.1676722
   PubMed Web of Science ®Google Scholar